A study highlights the importance of measuring activated proteins for selecting effective cancer therapies, improving patient outcomes.
Quiver AI Summary
Ignite Proteomics LLC announced the publication of a pivotal study in the British Journal of Cancer, which emphasizes the importance of measuring activated proteins in the AKT–mTOR signaling pathway for predicting cancer therapy responses, particularly in metastatic breast cancer. The research, conducted in collaboration with Perthera and the Side-Out Foundation, found that direct assessment of protein activation is a more effective predictor of patient outcomes than traditional genomic profiling. Specifically, it showed that patients with activated AKT–mTOR signaling experienced poorer responses to standard CDK4/6 inhibitor treatments despite their genomic mutations, highlighting the limitations of relying solely on genetic data. The study advocates for the integration of proteomic analysis into clinical practice to personalize cancer therapies based on the functional activity of proteins, potentially leading to improved patient outcomes. Ignite Proteomics offers a clinically validated assay based on this proteomic approach, aiming to enhance the precision of cancer treatment selections.
Potential Positives
- Publication of a significant study in the British Journal of Cancer highlights the critical role of measuring activated proteins for predicting cancer therapy responses.
- Demonstrates that Ignite Proteomics' RPPA-based assay can outperform traditional genomic profiling in guiding treatment decisions for metastatic breast cancer.
- Validates the company's approach to personalized therapy, potentially leading to better clinical outcomes for patients through tailored treatment strategies.
Potential Negatives
- The assertion that traditional genomic testing fails to accurately predict patient responses implies that existing practices may lead to ineffective treatment decisions, which could raise concerns about the company's previous reliance on such methodologies.
- Patients with active AKT–mTOR signaling showed worse responses to the standard care treatment, suggesting potential limitations or risk in the therapies offered by Ignite Proteomics and their partners.
- The press release emphasizes the need for more effective treatment strategies based on new methodologies, indicating that the current status quo is inadequate, which may reflect poorly on the company’s past operations and offerings.
FAQ
What is the significance of the new study published by Ignite Proteomics?
The study emphasizes that measuring protein activation is crucial for predicting patient responses to cancer therapies, surpassing genomic profiling.
How does the AKT-mTOR signaling pathway relate to cancer treatment?
Dysregulation of the AKT-mTOR pathway is linked to cancer progression, making its functional assessment essential for effective therapy selection.
What key finding did the research reveal about protein activation?
Patients with activated AKT-mTOR signaling showed poorer responses to standard treatments, indicating the need for proteomic profiling in therapy decisions.
How does the Ignite Proteomics assay improve cancer treatment personalization?
The assay measures both protein expression and activation levels, enabling oncologists to tailor therapies according to a tumor's unique proteomic profile.
What are the limitations of genomic profiling in cancer therapy selection?
Genomic profiling often fails to accurately predict protein activation levels, which can lead to less effective treatment choices for patients.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BACK Hedge Fund Activity
We have seen 6 institutional investors add shares of $BACK stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KESTRA ADVISORY SERVICES, LLC removed 44,395 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $49,722
- CITADEL ADVISORS LLC added 17,363 shares (+inf%) to their portfolio in Q3 2024, for an estimated $19,446
- WALLEYE CAPITAL LLC removed 13,831 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $15,490
- GEODE CAPITAL MANAGEMENT, LLC added 11,642 shares (+inf%) to their portfolio in Q3 2024, for an estimated $13,039
- TWO SIGMA SECURITIES, LLC added 11,545 shares (+inf%) to their portfolio in Q3 2024, for an estimated $12,930
- UBS GROUP AG removed 4,917 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5,507
- TOWER RESEARCH CAPITAL LLC (TRC) added 592 shares (+15.9%) to their portfolio in Q3 2024, for an estimated $663
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.
Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), announces the publication of a significant study in the
British Journal of Cancer
titled "Functional activation of the AKT–mTOR signalling axis in a real-world metastatic breast cancer cohort". This research underscores the critical importance of measuring functional protein activation within the AKT–mTOR signaling pathway to accurately predict patient responses to targeted cancer therapies.
Advancing Precision Oncology Through Direct Protein Activation Measurement
The study, coordinated by Perthera (McLean, VA) and a patient-centered initiative sponsored by the Side-Out Foundation, reveals that direct assessment of protein activation provides a superior method for predicting therapeutic outcomes compared to genomic profiling alone. The mutation status of tumors, determined through genomic analyses, did not correlate with protein activation levels and failed to adequately predict patient response.
Key Findings:
Protein Activation Predicts Therapeutic Response:
Patients exhibiting functional activation of the AKT–mTOR signaling axis demonstrated significantly worse response to standard of care first-line treatment with a CDK4/6 inhibitor.
Genomic Alterations Do Not Reflect Protein Activity:
The study found no correlation between genomic mutations in the PIK3CA, PTEN, or AKT genes and the activation status of corresponding proteins in the pathway.
Enhanced Clinical Outcomes Through Proteomic Profiling:
Utilizing protein activation analysis allowed for more precise identification of patients likely to benefit from endocrine therapy in combination with a CDK4/6 inhibitor.
"This study highlights the limitations of relying solely on genomic data for treatment decisions,"
said Mariaelena Pierobon, MD, MPH, senior author of the study.
"By directly measuring the activation status of proteins in the AKT–mTOR pathway, we may more accurately predict which patients will respond to specific targeted therapies."
Implications for the AKT–mTOR Signaling Pathway and Cancer Treatment
The AKT–mTOR pathway plays a pivotal role in cell growth, proliferation, and survival. Dysregulation of this pathway is implicated in the progression of various cancers, including metastatic breast cancer. Traditional genomic testing often misses the functional activation state of key proteins, potentially leading to less effective treatment choices.
Ignite Proteomics' Advanced Assay Offers a Solution:
Direct Measurement of Protein Activation:
The company's Reverse Phase Protein Array (RPPA)-based proteomic assay quantifies the phosphorylation (activation) status of proteins within the AKT–mTOR pathway.
Superior to Genomic Profiling:
By focusing on protein function rather than genetic mutations, the assay provides actionable insights that can guide more effective treatment strategies.
Clinical Utility Demonstrated in Real-World Cohort
The study analyzed tumor samples from a cohort of metastatic breast cancer patients. Key observations include:
Lack of Correlation Between Genomics and Proteomics:
Genomic alterations were not predictive of protein activation levels or patient outcomes.
Proteomic Profiling Predicts Response to CDK4/6 inhibitors:
Patients with an activated AKT–mTOR signaling axis showed worse clinical response to endocrine therapy in combination with a CDK4/6 inhibitor, evidenced by shorter progression-free survival.
Potential to Personalize Therapy:
The findings support the integration of proteomic analysis into clinical practice to tailor treatments based on functional protein activity.
"This research validates the potential of our proteomic assay in personalizing cancer treatment,"
said Justin Davis, PhD, Vice President of Research and Development at Ignite Proteomics and a co-author of the study.
"By measuring the actual drivers of tumor behavior – activated proteins – we enable clinicians to make more informed decisions that can significantly improve patient outcomes."
Building on Existing Evidence
This new study adds to existing evidence that measuring activated protein levels is key to predicting response – or non-response – to new therapies.
One study from 2022 deserves to be highlighted:
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
, published in
Clinical Cancer Research
. Researchers analyzed activated AKT protein levels by RPPA and also alterations in genes by standard genomic testing and concluded that “phosphorylated AKT (pAKT) levels exhibited a significant association with enriched clinical benefit of ipatasertib, and identified patients who received benefit in the absence of PIK3CA/AKT1/PTEN [genomic] alterations.”
Advancing Precision Medicine with Ignite Proteomics
Ignite Proteomics offers the only commercially available and clinically validated assay that measures both the expression and activation levels of drug targets in breast tumors. This innovative approach empowers oncologists to select therapies that are more likely to be effective based on the tumor's unique proteomic profile.
About Ignite Proteomics
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, specializes in advanced Reverse Phase Protein Array (RPPA) technology for cancer diagnostics. As a leader in protein activation analysis, and operating under a CLIA-accredited lab, Ignite provides a single test covering multiple markers to help doctors pinpoint the most suitable therapies, bridging the gap that gene-focused methods leave behind. Several key markers in the assay are protected by licensed patents.
About IMAC Holdings, Inc.
IMAC Holdings, Inc. strives to improve patient outcomes through innovative healthcare solutions. By combining strategic acquisitions and innovative technologies, IMAC Holdings remains committed to advancing personalized medicine. IMAC Holdings has begun the process to change its name and will soon be shown as IMAC Holdings, Inc, DBA Ignite Sciences, Inc.
For Additional Information, Please Contact:
Email:
Investors@imacholdings.com
Website:
www.igniteproteomics.com
Study location:
https://www.nature.com/articles/s41416-024-02852-y
FAIRLANE Trial:
https://pubmed.ncbi.nlm.nih.gov/34907082/
Non-Scientific Summary
In simple terms, this research shows that looking only at cancer’s DNA changes doesn’t always reveal which treatments will work. The actual proteins, and whether they’re “switched on,” matter more. Many modern cancer therapies either aim to shut down these active proteins or deliver potent drugs directly to them. By directly measuring protein activation, our test gives doctors better insight into which therapy is likely to be effective or which therapies should be avoided. This study – and a similar one we highlighted – both confirm that the “active” status of a protein can be the key to predicting how well a cancer drug will perform.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
